First Filing For Taisho/Tokuhon’s S-flurbiprofen
This article was originally published in PharmAsia News
Executive Summary
Taisho Pharmaceutical’s marketing authorization application in Japan for TT-063 is the first globally for a transdermal formulation of S-flurbiprofen for osteoarthritis.